Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 3/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680978 | 0.86 | APLNR (0.33) | CA2TNKSPARP1TNKS2HSD11B1 | |
| SCHEMBL20692023 | 0.86 | HSD11B1 (0.38) | CA1CA2CA5ACA9PRKAB2 | |
| SCHEMBL20681591 | 0.83 | HSD11B1 (0.42) | CA1CA2HSD11B1HSD17B2 | |
| SCHEMBL21962807 | 0.83 | CHRM2 (0.33) | TNKSPARP1TNKS2HSD11B1 | |
| SCHEMBL21962117 | 0.81 | PKM (0.45) | L3MBTL1CA1CA2CA9 | |
| SCHEMBL30162830 | 0.78 | NLRP3 (0.37) | CA1CA2CA9HSD11B1HSD17B2 | |
| SCHEMBL20692022 | 0.78 | NLRP3 (0.37) | CA1CA2CA9HSD11B1HSD17B2 | |
| SCHEMBL25033994 | 0.78 | L3MBTL1 (0.33) | L3MBTL1CA1CA2CA5ACA9 | |
| SCHEMBL19507910 | 0.77 | PDIA6 (0.49) | L3MBTL1CA1CA2CA5ACA9 | |
| SCHEMBL29927239 | 0.77 | PDIA6 (0.49) | L3MBTL1CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-06-10 | — | — | US | disclosed |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-06-10 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | L3MBTL1 2700/4885CA1 4250/4885CA2 2784/4885 |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP3, NLRP1, IAPP | L3MBTL1 2700/4885CA1 4250/4885CA2 2784/4885 |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4789/4885CA1 3665/4885CA2 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.